首页 | 本学科首页   官方微博 | 高级检索  
     


Moxifloxacin five‐day therapy versus placebo in acute bacterial rhinosinusitis
Authors:James A. Hadley MD  FACS  Ralph Mösges MD  PhD   FAAAAI  Martin Desrosiers MD  FRCSC  Daniel Haverstock MSc  David van Veenhuyzen MB  ChB   MPharmMed  Zeljka Herman‐Gnjidic MD  MSc
Affiliation:1. Department of Otolaryngology–Head and Neck Surgery, University of Rochester Medical Center, Rochester, New York, U.S.A.;2. Institute of Medical Statistics, Informatics and Epidemiology, University of Cologne, Cologne, Germany;3. Department of Otolaryngology–Head and Neck Surgery, Centre Hospitalier de l'Université de Montreal (CRCHUM) and McGill University Health Centre, Montreal, Quebec, Canada;4. Bayer HealthCare Pharmaceuticals, Pine Brook, New Jersey, U.S.A.;5. Bayer HealthCare Pharmaceuticals, Toronto, Ontario, Canada
Abstract:
Keywords:Moxifloxacin  placebo‐controlled trial  acute bacterial rhinosinusitis  Level of Evidence: 1b.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号